Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Vaxneuvance
Pharma
FDA signs off on Merck's pneumococcal vax for adults, Capvaxive
The FDA has approved the world’s first pneumococcal disease vaccine specifically designed for adults, signing off on Merck’s Capvaxive.
Kevin Dunleavy
Jun 17, 2024 5:03pm
FDA signs off on Pfizer's Prevnar 20 to vaccinate infants
Apr 28, 2023 9:15am
FDA grants Pfizer's Prevnar 20 priority review for pediatric use
Jan 6, 2023 10:20am
Pfizer shows key data, setting up pediatric nod for Prevnar 20
Aug 12, 2022 10:50am
Merck's Prevnar rival snags key pediatric nod
Jun 22, 2022 6:45am
FDA extends review of Merck's Vaxneuvance to July
Apr 1, 2022 9:52am
